Abstract-TheCX3C chemokine receptor 1 (CX3CR1), also known as fractalkine receptor or G-protein coupled receptor 13 (GPR13), is a protein in humans. 1 CX3CR1 binds the chemokine CX3CL1, also called fractalkine ligand or neurotactin. 2 CX3CR1 is expressed in the brain, spleen, and in subpopulations of leukocytes, cells of monocytic lineage, and neutrophils but also in lymphocytes, and associated with various cancer, cardiovascular and neurological diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). 3 CX3CR1 is an interesting therapeutic target, and many selective CX3CR1 antagonists have been developed. 4,5 Methyl (2-amino-5-(benzylthio)thiazolo[4,5-d]pyrimidin-7-yl)-Dleucinate (5) recently developed by AstraZeneca is a potent and selective CX3CR1 antagonist with Ki 8.3 and 1940 nM for CX3CR1 and CXCR2, respectively, and selectivity index (SI) 230. 6 CX3CR1 has also become a promising target for molecular imaging of CX3CR1-mediated diseases and image-guided therapy using positron emission tomography (PET) modality. However, radionuclides including carbon-11 and fluorine-18 labeled CX3CR1 antagonists are still not reported. In our previous work, we have developed carbon-11-labeled naphthalene-sulfonamides as potential radioligands for PET imaging of chemokine receptor 8 (CCR8), as indicated in Figure 1. 7 In this ongoing study, we first target CX3CR1 and develop radiolabeled CX3CR1 antagonists. Here we report the synthesis and preliminary biological evaluation of